

Revision date: 21-Apr-2015 Version: 2.0 Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Trade Name: VIROPTIC

Synonyms: Trifluridine Ophthalmic Solution

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Pfizer Inc Pfizer Ltd
Pfizer Pharmaceuticals Group Ramsgate Road
235 East 42nd Street Sandwich, Kent
New York, New York 10017 CT13 9NJ
1-800-879-3477 United Kingdom

1-800-879-3477 United Kingdom +00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300 International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Germ Cell Mutagenicity: Category 2 Carcinogenicity: Category 2

EU Classification:

EU Indication of danger: Mutagenic: Category 3

Carcinogenic: Category 3

EU Risk Phrases:

R40 - Limited evidence of a carcinogenic effect. R68 - Possible risk of irreversible effects.

Label Elements

Signal Word: Warning

Hazard Statements: H341 - Suspected of causing genetic defects

H351 - Suspected of causing cancer

Precautionary Statements: P201 - Obtain special instructions before use

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P405 - Store locked up

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0



Other Hazards **Australian Hazard Classification** (NOHSC):

No data available

Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Page 2 of 11

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Trifluridine	70-00-8	200-722-8	Mut. Cat.3,R68; Carc. Cat.3,R40	Carc.2 (H351) Muta.2 (H341)	1-5
Acetic acid	64-19-7	200-580-7	R10 C; R35	Skin Corr.1A (H314) Flam. Liq. 3 (H226)	<1.0
Sodium chloride	7647-14-5	231-598-3	Not Listed	Not Listed	*
Thimerosal	54-64-8	200-210-4	T+; R26/27/28; R33 N; R50/53	Acute Tox.2 (H300) Acute Tox. 1(H310) STOT RE 2 (H373) Acute Tox.2 (H330) Acute Aquatic 1 (H400) Chronic Aquatic 1 (H410)	<.01

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sodium acetate	127-09-3	204-823-8	Not Listed	Not Listed	*
Water for Injection	7732-18-5	231-791-2	Not Listed	Not Listed	*

Additional Information: * Proprietary

> Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Page 3 of 11

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion

Formation of toxic gases is possible during heating or fire.

Fine particles (such as mists) may fuel fires/explosions.

Advice for Fire-Fighters

Products:

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning /
Collecting:

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Additional Consideration for

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize generating airborne mists and vapors. Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Page 4 of 11

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Acetic acid

ACGIH Threshold Limit Value (TWA) ACGIH Threshold Limit Value (STEL) Australia STEL Australia TWA	10 ppm 15 ppm 15 ppm 37 mg/m ³ 10 ppm
Austria OEL - MAKs	25 mg/m ³ 10 ppm
Additio OEE MANS	25 mg/m ³
Belgium OEL - TWA	10 ppm 25 mg/m ³
Bulgaria OEL - TWA Cyprus OEL - TWA	25.0 mg/m ³ 10 ppm 25 mg/m ³
Czech Republic OEL - TWA	25 mg/m ³
Denmark OEL - TWA	10 ppm
Fotonio OFL TWA	25 mg/m ³
Estonia OEL - TWA	10 ppm 25 mg/m ³
Finland OEL - TWA	5 ppm
	13 mg/m ³
Germany - TRGS 900 - TWAs	10 ppm 25 mg/m ³
Germany (DFG) - MAK	10 ppm
	25 mg/m ³
Greece OEL - TWA	10 ppm
Hungary OEL TWA	25 mg/m ³ 25 mg/m ³
Hungary OEL - TWA Ireland OEL - TWAs	25 mg/m ²
TOTAL OLL TWAS	25 mg/m ³
Latvia OEL - TWA	10 ppm
	25 mg/m ³
Lithuania OEL - TWA	10 ppm 25 mg/m ³
Luxembourg OEL - TWA	10 ppm
Luxumbung GLL TWA	25 mg/m ³
Malta OEL - TWA	10 ppm
COULA EL LIBELO TIMA	25 mg/m ³
OSHA - Final PELS - TWAs:	10 ppm 25 mg/m ³
Poland OEL - TWA	15 mg/m ³
Portugal OEL - TWA	10 ppm
Romania OEL - TWA	10 ppm
	25 mg/m ³

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Slovakia OEL - TWA 10 ppm

25 mg/m³ Slovenia OEL - TWA 10 ppm

25 mg/m³ Spain OEL - TWA 10 ppm

25 mg/m³ **Sweden OEL - TWAs** 5 ppm

13 mg/m³

Switzerland OEL -TWAs 10 ppm 25 mg/m³

25 mg/m³ Vietnam OEL - TWAs

Sodium chloride

Latvia OEL - TWA 5 mg/m³ 5 mg/m³ Lithuania OEL - TWA

Trifluridine

Pfizer Occupational Exposure OEB 4 (control exposure to the range of 1ug/m³ to <10ug/m³)

Band (OEB):

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

Page 5 of 11

contamination levels below the exposure limits listed above in this section.

Personal Protective

Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE). **Equipment:**

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eves: Wear safety glasses or goggles if eye contact is possible.

Impervious protective clothing is recommended if skin contact with drug product is possible and Skin:

for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear

an appropriate respirator with a protection factor sufficient to control exposures to the bottom of

Mixture

the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available. Sterile solution **Physical State:** Color: No data available. No data available. Odor: **Odor Threshold:**

Molecular Formula: Mixture **Molecular Weight:**

No data available **Solvent Solubility:** Water Solubility: No data available

5.5-6.0 pH:

Melting/Freezing Point (°C): No data available **Boiling Point (°C):** No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Sodium acetate No data available Sodium chloride No data available **Thimerosal**

Page 6 of 11

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Trifluridine

No data available

Acetic acid

No data available

Water for Injection No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

No data available
No data available
No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep

away from heat sources and electrostatic discharge.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition

Products:

No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Short Term: Mild eye irritation.

Known Clinical Effects: Adverse effects most commonly reported in clinical use include burning/stinging of the eyes,

irritation, swelling of the eye hypersensitivity reactions, increased intra-ocular pressure

(glaucoma).

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Thimerosal

Rat Oral LD50 75 mg/kg

00000500

Page 7 of 11

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Mouse Oral LD50 91 mg/kg Rat Subcutaneous LD50 98mg/kg

Trifluridine

Rat Intravenous LD50 2946 mg/kg Rat Oral LD50 > 4379mg/kg Mouse Oral LD50 > 4379mg/kg

Acetic acid

Rat Oral LD50 3530 mg/kg Mouse Inhalation LC50 5000ppm

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Thimerosal

Eye Irritation Rabbit Mild

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Trifluridine

Embryo / Fetal Development Rat Subcutaneous1 mg/kg/day NOAEL Fetotoxicity, Not teratogenic

Embryo / Fetal Development Rabbit Subcutaneous 1 mg/kg/day NOAEL Fetotoxicity, Not Teratogenic, Fetal mortality

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Trifluridine

In Vitro Sister Chromatid Exchange Hamster Lymphocytes Positive

Cell Transformation Assay Mouse Negative

Forward Mutation Assay Hamster Lung Cells Negative

Chromosome Aberration Rat Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Trifluridine

2 Year(s) Rat Subcutaneous 1.5 mg/kg/day LOAEL Tumors, Mammary gland, Gastrointestinal system, Liver, Spleen 2 Year(s) Mouse Subcutaneous 1 mg/kg/day LOAEL Tumors, Gastrointestinal system, Female reproductive system, Male reproductive system

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Product Level Toxicity Data

00232528

Page 8 of 11

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity

Study Type Species Route Dosage End Point Effect(s)

(mg/kg/day)
Embryo/Fetal Development Rabbit Topical, eye 1% NOAEL Not teratogenic

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been investigated. Releases to the

environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Acetic acid

Pimephales promelas (Fathead Minnow)LC-501 Hours> 315 mg/LPimephales promelas (Fathead Minnow)LC-5024 Hours122 mg/LMysidopsis bahia (Mysid Shrimp)LC-5048 Hours100-300 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Page 9 of 11

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0

15. REGULATORY INFORMATION

Canada - WHMIS: Classifications

WHMIS hazard class:

D2a very toxic materials

This product has been classified in accordance with the hazard criteria of the CPR and the SDS contains all of the information required by the CPR.



Trifluridine

CERCLA/SARA 313 Emission reporting Not Listed **California Proposition 65** Not Listed **EU EINECS/ELINCS List** 200-722-8

Acetic acid

CERCLA/SARA 313 Emission reporting Not Listed **CERCLA/SARA Hazardous Substances** 5000 lb and their Reportable Quantities: 2270 kg **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Present Australia (AICS): Standard for the Uniform Scheduling Schedule 2 for Drugs and Poisons: Schedule 5 Schedule 6 200-580-7 **EU EINECS/ELINCS List**

Sodium acetate

CERCLA/SARA 313 Emission reporting Not Listed **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS/ELINCS List** 204-823-8

Sodium chloride

CERCLA/SARA 313 Emission reporting Not Listed **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS/ELINCS List** 231-598-3

Thimerosal

CERCLA/SARA 313 Emission reporting Not Listed Not Listed California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Present Present Australia (AICS):

REACH - Annex XVII - Restrictions on Certain Use restricted. See item 18.

Dangerous Substances:

Page 10 of 11

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0

15. REGULATORY INFORMATION

EU EINECS/ELINCS List 200-210-4

Water for Injection

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Not Listed

Present

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects

Carcinogenicity-Cat.2; H351 - Suspected of causing cancer

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage

Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed

Acute toxicity, dermal-Cat.1; H310 - Fatal in contact with skin

Acute toxicity, inhalation-Cat.2; H330 - Fatal if inhaled

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure

Flammable liquids-Cat.3; H226 - Flammable liquid and vapor

Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life

Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

Carcinogenic: Category 3 Mutagenic: Category 3

C - Corrosive T+ - Very toxic

N - Dangerous for the environment

R10 - Flammable.

R33 - Danger of cumulative effects.

R35 - Causes severe burns.

R40 - Limited evidence of a carcinogenic effect

R68 - Possible risks of irreversible effects.

R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed.

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Safety

data sheets for individual ingredients.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 15 - Regulatory

Information. Updated Section 16 - Other Information.

Revision date: 21-Apr-2015

Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Prepared by:

Page 11 of 11

Material Name: Viroptic Ophthalmic Solution Sterile 1%

Revision date: 21-Apr-2015 Version: 2.0

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
